Bade Brett, Furukawa Brian, Tanner Nichole T
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina.
Semin Respir Crit Care Med. 2014 Dec;35(6):636-44. doi: 10.1055/s-0034-1395498. Epub 2014 Dec 2.
Convex probe endobronchial ultrasound (EBUS) is a minimally invasive diagnostic technique that allows real-time sampling of mediastinal and hilar lymph nodes and central pulmonary lesions. Its utility in diagnosing both malignant and nonmalignant diseases has led to an increased uptake and use by pulmonologists over the past decade. Because of the robust evidence supporting its safety and diagnostic yield, EBUS is now the first guideline recommended test for staging in non-small cell lung cancer (NSCLC). It has also a role in providing tissue for molecular analysis, thereby guiding in the selection of agents in the new era of personalized chemotherapies in the treatment of NSCLC. The following review highlights the evidence for EBUS in diagnosing mediastinal pathology and addresses technique, training, and competency and future directions for this technology.
凸阵探头支气管内超声(EBUS)是一种微创诊断技术,可对纵隔和肺门淋巴结以及中央肺部病变进行实时采样。在过去十年中,其在诊断恶性和非恶性疾病方面的效用促使肺科医生对其的采用和使用增加。由于有强有力的证据支持其安全性和诊断率,EBUS现在是首个指南推荐的非小细胞肺癌(NSCLC)分期检测方法。它在提供用于分子分析的组织方面也发挥作用,从而在NSCLC治疗的个性化化疗新时代指导药物选择。以下综述重点介绍了EBUS在诊断纵隔病变方面的证据,并探讨了该技术的操作、培训、能力以及未来发展方向。